{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:03:52Z","timestamp":1792213432262,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jbspin.2025.105938","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:18:24Z","timestamp":1751426304000},"page":"105938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1869-0771","authenticated-orcid":false,"given":"Alice","family":"Tison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Escoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kostine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2025.105938_bib0390","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105938_bib0395","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0400","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0405","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jbspin.2025.105938_bib0410","year":"2024"},{"key":"10.1016\/j.jbspin.2025.105938_bib0415","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.rdc.2024.02.006","article-title":"The need for classification criteria of immune checkpoint inhibitor-induced inflammatory arthritis: a scoping review","volume":"50","author":"Ghosh","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2025.105938_bib0420","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.rdc.2024.01.001","article-title":"Pre-existing autoimmune diseases and immune checkpoint inhibitors for cancer treatment: considerations about initiation, flares, immune-related adverse events, and cancer progression","volume":"50","author":"Sparks","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2025.105938_bib0425","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0430","doi-asserted-by":"crossref","first-page":"102687","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies","volume":"19","author":"Xie","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2025.105938_bib0435","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0440","doi-asserted-by":"crossref","first-page":"152335","DOI":"10.1016\/j.semarthrit.2023.152335","article-title":"Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer","volume":"64","author":"McCarter","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105938_bib0445","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0450","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbspin.2025.105938_bib0455","doi-asserted-by":"crossref","first-page":"114172","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbspin.2025.105938_bib0460","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0465","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/rheumatology\/key234","article-title":"High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis","volume":"57","author":"Ford","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105938_bib0470","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/kead438","article-title":"Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis","volume":"63","author":"Cappelli","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105938_bib0475","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.rdc.2024.01.003","article-title":"The utility of laboratory investigations for the assessment and management of rheumatic immune related adverse events","volume":"50","author":"Ladouceur","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2025.105938_bib0480","doi-asserted-by":"crossref","first-page":"2204754","DOI":"10.1080\/2162402X.2023.2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Daban","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jbspin.2025.105938_bib0485","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1002\/cam4.4675","article-title":"Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study","volume":"11","author":"Barth","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.jbspin.2025.105938_bib0490","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0495","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105938_bib0500","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105938_bib0505","doi-asserted-by":"crossref","first-page":"105403","DOI":"10.1016\/j.jbspin.2022.105403","article-title":"Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis","volume":"89","author":"Veccia","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105938_bib0510","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105938_bib0515","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105938_bib0520","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2025.105938_bib0525","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0530","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature","volume":"25","author":"Chan","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jbspin.2025.105938_bib0535","doi-asserted-by":"crossref","first-page":"103589","DOI":"10.1016\/j.autrev.2024.103589","article-title":"Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms","volume":"23","author":"Hysa","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2025.105938_bib0540","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jbspin.2025.105938_bib0545","doi-asserted-by":"crossref","first-page":"e2022105","DOI":"10.5826\/dpc.1203a105","article-title":"Is a triggering role or a causative role of PD-1\/PDL-1 inhibitors in the development of paraneoplastic dermatomyositis?","volume":"12","author":"Starace","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.jbspin.2025.105938_bib0550","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0022034519850564","article-title":"Profiling autoantibodies against salivary proteins in Sicca conditions","volume":"98","author":"Burbelo","year":"2019","journal-title":"J Dent Res"},{"key":"10.1016\/j.jbspin.2025.105938_bib0555","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jbspin.2025.105938_bib0560","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0565","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.rdc.2024.02.002","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: current approaches to management","volume":"50","author":"Singh","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2025.105938_bib0570","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105938_bib0575","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s12094-022-02840-9","article-title":"Diagnostic impact of 18F-FDG PET\/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy","volume":"24","author":"Tatar","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0580","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging findings in patients with immune checkpoint inhibitor-induced arthritis","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jbspin.2025.105938_bib0585","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0590","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0595","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.rdc.2024.02.004","article-title":"Immune checkpoint inhibitor-induced Sicca syndrome","volume":"50","author":"Bitoun","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl. 118","key":"10.1016\/j.jbspin.2025.105938_bib0600","first-page":"114","article-title":"Sicca\/Sj\u00f6gren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0605","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, Version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jbspin.2025.105938_bib0610","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/rheumatology\/keae099","article-title":"Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement","volume":"64","author":"Vermeulen","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105938_bib0615","doi-asserted-by":"crossref","first-page":"101805","DOI":"10.1016\/j.berh.2022.101805","article-title":"Treatment of rheumatic adverse events of cancer immunotherapy","volume":"36","author":"Reid","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0620","doi-asserted-by":"crossref","first-page":"e000906","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105938_bib0625","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1136\/annrheumdis-2020-217225","article-title":"Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy","volume":"81","author":"Martin de Fremont","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105938_bib0630","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0635","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0640","doi-asserted-by":"crossref","first-page":"e002612","DOI":"10.1136\/rmdopen-2022-002612","article-title":"Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study","volume":"8","author":"De La Fuente","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105938_bib0645","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0650","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbspin.2025.105938_bib0655","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rdc.2024.02.007","article-title":"Impact of non-steroidal anti-inflammatory drugs, glucocorticoids, and disease-modifying anti-rheumatic drugs on cancer response to immune checkpoint inhibitor therapy","volume":"50","author":"Chan","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2025.105938_bib0660","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/10428194.2023.2262641","article-title":"Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab","volume":"64","author":"Stuver","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jbspin.2025.105938_bib0665","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbspin.2025.105938_bib0670","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jbspin.2025.105938_bib0675","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jbspin.2025.105938_bib0680","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105938_bib0685","doi-asserted-by":"crossref","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jbspin.2025.105938_bib0690","doi-asserted-by":"crossref","first-page":"e004308","DOI":"10.1136\/rmdopen-2024-004308","article-title":"Successful management of pre-existing psoriatic arthritis through targeting the IL-23\/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series","volume":"10","author":"Li","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105938_bib0695","doi-asserted-by":"crossref","first-page":"e009345","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jbspin.2025.105938_bib0700","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jbspin.2025.105938_bib0705","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2025.105938_bib0710","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbspin.2025.105938_bib0715","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","article-title":"Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma","volume":"4","author":"V\u00e1raljai","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jbspin.2025.105938_bib0720","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.annonc.2020.12.001","article-title":"Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review","volume":"32","author":"Deftereos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0725","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/cancers16030611","article-title":"The JAK-STAT pathway as a therapeutic strategy in cancer patients with immune checkpoint inhibitor-induced colitis: a narrative review","volume":"16","author":"Gravina","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbspin.2025.105938_bib0730","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2025.105938_bib0735","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2025.105938_bib0740","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbspin.2025.105938_bib0745","doi-asserted-by":"crossref","first-page":"eade8520","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jbspin.2025.105938_bib0750","doi-asserted-by":"crossref","first-page":"1459777","DOI":"10.3389\/fimmu.2024.1459777","article-title":"Combination of JAK inhibitor and immune checkpoint inhibitor in clinical trials: a breakthrough","volume":"15","author":"Dong","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2025.105938_bib0755","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jbspin.2025.105938_bib0760","doi-asserted-by":"crossref","first-page":"e003795","DOI":"10.1136\/rmdopen-2023-003795","article-title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study","volume":"9","author":"Ladouceur","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105938_bib0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.revmed.2023.12.003","article-title":"[Managing cancer immunotherapy toxicities: challenges and rechallenges for (young) internists]","volume":"45","author":"Guitton","year":"2024","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jbspin.2025.105938_bib0770","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/CCO.0000000000001014","article-title":"Single agent vs. combination immunotherapy in advanced melanoma: a review of the evidence","volume":"36","author":"Benhima","year":"2024","journal-title":"Curr Opin Oncol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:39:41Z","timestamp":1767800381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X25001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1297319X25001009"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105938","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105938"}}